TY - JOUR
T1 - Myeloproliferative Neoplasms, Version 3.2022
AU - Gerds, Aaron T.
AU - Gotlib, Jason
AU - Ali, Haris
AU - Bose, Prithviraj
AU - Dunbar, Andrew
AU - Elshoury, Amro
AU - George, Tracy I.
AU - Gundabolu, Krishna
AU - Hexner, Elizabeth
AU - Hobbs, Gabriela S.
AU - Jain, Tania
AU - Jamieson, Catriona
AU - Kaesberg, Paul R.
AU - Kuykendall, Andrew T.
AU - Madanat, Yazan
AU - McMahon, Brandon
AU - Mohan, Sanjay R.
AU - Nadiminti, Kalyan V.
AU - Oh, Stephen
AU - Pardanani, Animesh
AU - Podoltsev, Nikolai
AU - Rein, Lindsay
AU - Salit, Rachel
AU - Stein, Brady L.
AU - Talpaz, Moshe
AU - Vachhani, Pankit
AU - Wadleigh, Martha
AU - Wall, Sarah
AU - Ward, Dawn C.
AU - Bergman, Mary Anne
AU - Hochstetler, Cindy
N1 - Publisher Copyright:
© JNCCN.
PY - 2022/9
Y1 - 2022/9
N2 - The classic Philadelphia chromosome-negativemyeloproliferative neoplasms (MPN) consist ofmyelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for themanagement of MPN in adults. TheGuidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.
AB - The classic Philadelphia chromosome-negativemyeloproliferative neoplasms (MPN) consist ofmyelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for themanagement of MPN in adults. TheGuidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.
UR - http://www.scopus.com/inward/record.url?scp=85137545298&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2022.0046
DO - 10.6004/jnccn.2022.0046
M3 - Article
C2 - 36075392
AN - SCOPUS:85137545298
SN - 1540-1405
VL - 20
SP - 1033
EP - 1062
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 9
ER -